Young, S. A. E. | bioRxiv Science

bioRxiv2023

From breast cancer cell homing to the onset of early bone metastasis: dynamic bone (re)modeling as a driver of osteolytic disease

Breast cancer often metastasizes to bone causing osteolytic lesions. Structural and biophysical changes are rarely studied, yet are hypothesized to influence metastatic progression. Here, we developed a mouse model of early bone metastasis and multimodal 3D imaging to quantify cancer cell homing, dynamic bone (re)modeling and onset of bone metastasis. Using 3D light sheet fluorescence microscopy, we show eGFP+ cancer cells and small clusters in 3D (intact) bones. We detect early bone lesions using time-lapse in vivo microCT and reveal altered bone (re)modeling in absence of detectable lesions. With a new microCT image analysis tool, we detect and track the growth of early bone lesions over time. We show that cancer cells home in all bone compartments, while osteolytic lesions are only detected in the metaphysis, a region of high (re)modeling. Our study provides novel insights of dynamic bone (re)modeling as a driver during the early phase of metastasis.

bioengineering↗

bioRxiv2023

Quiescence-inducing 3D-engineered matrix uncovers mechanosensitive and drug protective FHL2-p21 signaling axis

Resected tumors frequently relapse with distant metastasis, despite systemic treatment. Cellular dormancy has been identified as an important mechanism underlying such drug resistance enabling late relapse. Nonetheless, hurdles associated with detection and isolation of disseminated cancer cells (DCCs) in disease-free patients urge the need for in vitro models of dormant cells suited for drug discovery. Here, we explore dormancy-inducing 3D-engineered matrices, which generate mechanical confinement and induce growth arrest and survival against chemotherapy in cancer cells. We characterized the dormant phenotype of solitary cells by P-ERKlow:P-p38high dormancy signaling ratio, along with Ki67-expression. As underlying mechanism, we identified stiffness-dependent nuclear localization of the four-and-a-half LIM domains 2 (FHL2) protein, leading to p53-independent high p21Cip1/Waf1 nuclear expression, validated in murine and human tissue. Suggestive of a resistance-causing role, cells in the dormancy-inducing matrix became sensitive against chemotherapy upon FHL2 downregulation. Thus, our biomaterial-based approach will enable systematic screens for novel compounds suited to eradicate potentially relapsing, dormant cancer cells. TeaserUsing semi-synthetic bioengineered hydrogels, we reveal a mechanosensitive and drug protective mechanism of dormant cancer cells in tissues

bioengineering↗